Our latest news
What We’re Working On
Media Contact
Katie Engleman
katie@1abmedia.com
Bringing Meaningful Therapies from One to Many
-
June 18th, 2025
Actio Biosciences Secures $66 Million Series B Financing to Advance Genetics-Driven Pipeline of Small Molecule Therapeutics for Rare and Common Diseases
Read More -
April 9th, 2025
Actio Biosciences to Participate in Piper Sandler Spring Biopharma Symposium
Read More -
March 3rd, 2025
Actio Biosciences Announces First Participant Dosed in Phase 1 Clinical Trial of ABS-0871, a Novel TRPV4 Inhibitor, for the Treatment of Charcot Marie Tooth Disease 2C
Read More -
February 25th, 2025
Actio Biosciences to Participate in Upcoming Investor Conferences
Read More -
January 8th, 2025
Actio Biosciences Expands Leadership Team with Appointment of Cayce Denton as Chief Financial Officer
Read More